What are the key questions that future research on eculizumab aims to answer?

Nov 18, 2022 ... Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study Eculizumab blocks the complement pathway. ▫ Humanised version of anti-C5 antibody, binding specifically to the complement protein. C5 (NHS 2012). Mar 21, 2025 ... Eculizumab Biosimilars in PNH: Working Towards Broader Patient Access ... Eculizumab was the first drug approved for the treatment of complement- ... Feb 12, 2025 ... These studies suggest that eculizumab and ravulizumab are safe and effective treatments for people with AQP4-Ab+ NMOSD. Jul 14, 2017 ... What is already known about this topic? Eculizumab (Soliris, Alexion Pharmaceuticals), a terminal complement inhibitor, is associated with a ... The generic drug name is eculizumab (ek-u-liz-oo-mab). Soliris® is a brand ... Eculizumab is a monoclonal antibody, a type of targeted therapy. It. Nov 14, 2024 ... The brand names of the eculizumab biosimilars are Bekemv and Epysqli. They are only available for the treatment of PNH and aHUS in countries which have ... Apr 3, 2025 ... Eculizumab (brand names Soliris, Bkemv, Epysqli) is used to treat paroxysmal nocturnal hemoglobinuria (PNH) in adults, and a rare chronic blood ... Indicated for paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. Doses 1-4: 600 mg IV qWeek for first 4 weeks, followed by Dose 5: 900 mg IV 1 week ... As anti-C5 therapy like eculizumab is the only treatment for patients with aHUS, optimizing treatment is indispensable. The drug label states that a trough ...